Xenetic Q2 2026 net loss $0.9M; royalty revenue up 12% to $0.7M

Xenetic Biosciences, Inc.

2026-Q2 EPS reported -$0.60 revenue$1,467,524

Net loss $0.9M vs $0.7M Q2 2025; cash $6.5M at June 30, 2026 vs $7.9M at Dec 31, 2025.
Royalty revenue $0.7M, +12% YoY, from Takeda sublicense; first-half royalties ~$1.5M.
R&D expenses $0.6M (-16% YoY); G&A $1.1M (+64%) on strategic review legal costs.
ASCO data: DNase I enhanced CAR T expansion, persistence, tumor control; PeriNess study approved for LBCL.
Strategic review process ongoing; interim CEO James Parslow emphasizes disciplined capital allocation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.